CHINOOK THERAPEUTICS, INC. Quarterly Operating Income (Loss) in USD from Q1 2014 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Chinook Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2014 to Q2 2023.
  • Chinook Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2023 was -$72.6M, a 98% decline year-over-year.
  • Chinook Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2023 was -$252M, a 192% decline year-over-year.
  • Chinook Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$185M, a 86.9% decline from 2021.
  • Chinook Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$99M, a 76.1% decline from 2020.
  • Chinook Therapeutics, Inc. annual Operating Income (Loss) for 2020 was -$56.2M, a 182% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$252M -$72.6M -$35.9M -98% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-07
Q1 2023 -$216M -$61.4M -$30.6M -99.3% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-09
Q4 2022 -$185M -$59.9M -$72.3M -584% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-27
Q3 2022 -$113M -$57.7M -$26.7M -86% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$86.1M -$36.7M +$6.59M +15.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$92.7M -$30.8M +$6.33M +17.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$99M $12.4M +$46.3M Oct 1, 2021 Dec 31, 2021 10-K 2023-02-27
Q3 2021 -$145M -$31M -$20.5M -196% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$125M -$43.3M -$35.5M -458% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$89.3M -$37.1M -$33.1M -808% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$56.2M -$33.9M -$83.5M -168% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $27.3M -$10.5M +$14.1M +57.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $13.2M -$7.75M +$12.4M +61.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $859K -$4.09M +$20.8M +83.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 -$20M $49.6M +$77.6M Oct 1, 2019 Dec 31, 2019 10-K 2021-04-07
Q3 2019 -$97.6M -$24.5M +$367K +1.47% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$97.9M -$20.1M +$5.65M +21.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-03
Q1 2019 -$104M -$24.9M -$2.22M -9.76% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 -$101M -$28M +$74K +0.26% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$101M -$24.9M +$4.36M +14.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$106M -$25.8M -$1.85M -7.74% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 -$104M -$22.7M +$2.51M +9.96% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$106M -$28.1M -$2.94M -11.7% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-09
Q3 2017 -$104M -$29.3M -$5.32M -22.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-30
Q2 2017 -$98.2M -$23.9M -$27.2M -834% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-01
Q1 2017 -$71M -$25.2M +$823K +3.16% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-02
Q4 2016 -$71.9M -$25.1M -$28M -990% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 -$43.9M -$23.9M -$24.4M -5734% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-31
Q2 2016 -$19.5M $3.26M +$12.8M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-02
Q1 2016 -$32.3M -$26M -$18.8M -257% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-02
Q4 2015 -$13.6M $2.83M +$3.95M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-01
Q3 2015 -$17.5M $425K +$5.78M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-02
Q2 2015 -$23.3M -$9.53M -$2.98M -45.5% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-03
Q1 2015 -$20.3M -$7.28M -$1.19M -19.6% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
Q4 2014 -$19.1M -$1.13M Oct 1, 2014 Dec 31, 2014 10-K 2017-03-01
Q3 2014 -$5.35M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-23
Q2 2014 -$6.55M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-11
Q1 2014 -$6.09M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.